Mutated influenza A virus exhibiting reduced susceptibility to baloxavir marboxil from an experimentally infected horse

References

1. Singh RK, Dhama K, Karthik K, Khandia R, Munjal A et al. A comprehensive review on equine influenza virus: etiology, epidemiology, pathobiology, advances in developing diagnostics, vaccines, and control strategies. Front Microbiol 2018; 9:9 [View Article]
   [Google Scholar]
2. Yamanaka T, Niwa H, Tsujimura K, Kondo T, Matsumura T. Epidemic of equine influenza among vaccinated racehorses in Japan in 2007. J Vet Med Sci 2008; 70:623–625 [View Article]
   [Google Scholar]
3. Rees WA, Harkins JD, Lu M, Holland RE, Lehner AF et al. Pharmacokinetics and therapeutic efficacy of rimantadine in horses experimentally infected with influenza virus A2. Am J Vet Res 1999; 60:888–894
   [Google Scholar]
4. Yamanaka T, Tsujimura K, Kondo T, Hobo S, Matsumura T. Efficacy of oseltamivir phosphate to horses inoculated with equine influenza A virus. J Vet Med Sci 2006; 68:923–928 [View Article]
   [Google Scholar]
5. Yamanaka T, Bannai H, Nemoto M, Tsujimura K, Kondo T et al. Efficacy of a single intravenous dose of the neuraminidase inhibitor peramivir in the treatment of equine influenza. Vet J 2012; 193:358–362 [View Article]
   [Google Scholar]
6. Koszalka P, Tilmanis D, Hurt AC. Influenza antivirals currently in late-phase clinical trial. Influenza Other Respir Viruses 2017; 11:240–246 [View Article]
   [Google Scholar]
7. Takashita E, Kawakami C, Ogawa R, Morita H, Fujisaki S et al. Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019. Euro Surveill 2019; 24:pii=1900170 [View Article]
   [Google Scholar]
8. Taniguchi K, Ando Y, Nobori H, Toba S, Noshi T et al. Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil. Sci Rep 2019; 9:3466 [View Article]
   [Google Scholar]
9. Koszalka P, Tilmanis D, Roe M, Vijaykrishna D, Hurt AC. Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012-2018. Antiviral Res 2019; 164:91–96 [View Article]
   [Google Scholar]
10. Noshi T, Kitano M, Taniguchi K, Yamamoto A, Omoto S et al. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antiviral Res 2018; 160:109–117 [View Article]
    [Google Scholar]
11. Omoto S, Speranzini V, Hashimoto T, Noshi T, Yamaguchi H et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep 2018; 8:9633 [View Article]
    [Google Scholar]
12. Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD et al. Baloxavir Marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med 2018; 379:913–923 [View Article]
    [Google Scholar]
13. Takashita E, Kawakami C, Morita H, Ogawa R, Fujisaki S et al. Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018. Euro Surveill 2019; 24:pii=1800698 [View Article]
    [Google Scholar]
14. Witkowska-Piłaszewicz OD, Żmigrodzka M, Winnicka A, Miśkiewicz A, Strzelec K et al. Serum amyloid A in equine health and disease. Equine Vet J 2019; 51:293–298 [View Article]
    [Google Scholar]
15. Aoki FY, Boivin G, Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther 2007; 12:603–616
    [Google Scholar]
16. Rivailler P, Perry IA, Jang Y, Davis CT, Chen L-M et al. Evolution of canine and equine influenza (H3N8) viruses co-circulating between 2005 and 2008. Virology 2010; 408:71–79 [View Article]
    [Google Scholar]
17. Yamanaka T, Cullinane A, Gildea S, Bannai H, Nemoto M et al. The potential impact of a single amino-acid substitution on the efficacy of equine influenza vaccines. Equine Vet J 2015; 47:456–462 [View Article]
    [Google Scholar]
18. Yamanaka T, Tsujimura K, Kondo T, Matsumura T, Ishida H et al. Infectivity and pathogenicity of canine H3N8 influenza A virus in horses. Influenza Other Respir Viruses 2010; 4:345–351 [View Article]
    [Google Scholar]
19. Yamanaka T, Nemoto M, Bannai H, Tsujimura K, Kondo T et al. Evaluation of twenty-two rapid antigen detection tests in the diagnosis of equine influenza caused by viruses of H3N8 subtype. Influenza Other Respir Viruses 2016; 10:127–133 [View Article]
    [Google Scholar]
20. Yamanaka T, Nemoto M, Tsujimura K, Kondo T, Matsumura T. Interspecies transmission of equine influenza virus (H3N8) to dogs by close contact with experimentally infected horses. Vet Microbiol 2009; 139:351–355 [View Article]
    [Google Scholar]
21. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938; 27:493–497
    [Google Scholar]
22. Hoffmann E, Stech J, Guan Y, Webster RG, Perez DR. Universal primer set for the full-length amplification of all influenza A viruses. Arch Virol 2001; 146:2275–2289 [View Article]
    [Google Scholar]
23. Nemoto M, Yamanaka T, Bannai H, Tsujimura K, Kokado H. Complete genomic sequences of H3N8 equine influenza virus strains used as vaccine strains in Japan. Genome Announc 2018; 6:e00172–18 [View Article]
    [Google Scholar]